Pretreatment Plasma Levels of Fibrinopeptide-A (FPA), D-Dimer (DD), and von Willebrand Factor (vWF) in Patients with Ovarian Carcinoma

Gadducci, Angiolo; Baicchi, U; Marrai, R; Bravo, B Del; Fosella, Pv; Facchini, V.

doi:10.1006/gyno.1994.1146

Cited by 55 publications

(36 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients with GBM in our study had supraphysiological VWF:Ag levels and the higher was the VWF level the shorter was the survival rendering VWF:Ag levels a putative prognostic factor. Such a prognostic role for VWF has been shown in patients with other type of cancer, being high VWF levels associated with disease stage, 33, 34, 35, 36, 37, presence of metastases and/or lymph node status 33, 34, 36, 37, tumor size and residual disease after surgery 35. All in all, this study showed a significantly reduced survival in patients with GBMs and preoperative high levels of VWF:Ag in plasma irrespective of age.…”

Section: Discussionmentioning

confidence: 76%

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

et al. 2016

View full text Add to dashboard Cite

Circulating biomarker for malignant gliomas could improve both differential diagnosis and clinical management of brain tumor patients. Among all gliomas, glioblastoma (GBM) is considered the most hypervascularized tumor with activation of multiple proangiogenic signaling pathways that enhance tumor growth. To investigate whether preoperative antigen plasma level of von Willebrand Factor (VWF:Ag) might be possible marker for GBM onset, progression, and prognosis, we retrospectively examined 57 patients with histological diagnosis for GBM and 23 meningiomas (MNGs), benign intracranial expansive lesions, enrolled as controls. Blood samples were collected from all the patients before tumor resection. Plasma von Willebrand Factor (VWF):Ag levels were determined by using a latex particle‐enhanced immunoturbidimetric assay. The median levels of vWF:Ag were significantly higher in GBMs than in meningiomas (MNGs) (183 vs. 133 IU/dL, P = 0.01). The cumulative 1‐year survival was significantly shorter in patients with VWF:Ag levels >200 IU/dL than in those with levels <200 IU/dL and increased VWF levels were associated with a threefold higher risk of death in GBM patients. Our data suggest that VWF:Ag could be a circulating biomarker of disease malignancy, that could be considered, in association with other genetic and epigenetic factors, currently available in the GBM management. Future studies should investigate whether plasma VWF:Ag levels could also be used to monitor therapeutic effects and whether it may have a prognostic value.

show abstract

Section: Discussionmentioning

confidence: 76%

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Notably, the levels of VWF were comparable in patients in presence or absence of HCC. It has been suggested that VWF plasma levels may be of prognostic significance in patients with solid tumors [46][47][48], but the prognostic significance of VWF in HCC is absent, perhaps because of the effects of the underlying cirrhotic disease on VWF levels.…”

Section: Discussionmentioning

confidence: 99%

No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma

Alkozai¹,

Porte²,

Adelmeijer³

et al. 2015

Thrombosis Research

View full text Add to dashboard Cite

“…Elevated levels of angiogenic growth factors, proteases, and endothelial adhesion molecules have been detected in sera of patients with malignant disease (Dirix et al, 1997). These important promoters of tumour angiogenesis include VEGF (Takahashi et al, 1994), bFGF (Fujimoto et al, 1995), urokinase-type plasminogen activator and its soluble receptor (Xu et al, 1997), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) (Banks et al, 1993), and von Willebrand's factor (vWF) (Gadducci et al, 1994). Of the many mediators of angiogenesis, VEGF and bFGF are thought to play the most important roles and thus have been frequently measured as potential surrogate markers of antiangiogenic activity in many Phase I/II studies.…”

Section: Serum Plasma and Urine Factorsmentioning

confidence: 99%

Surrogate markers in antiangiogenesis clinical trials

et al. 2003

View full text Add to dashboard Cite

Novel antiangiogenic agents currently being developed may ultimately be more effective against solid tumours and less toxic than cytotoxic chemotherapy. As a result of the early clinical trials of angiogenesis inhibitors, investigators are beginning to appreciate the complexity of targeting angiogenesis and the realisation that developing clinically useful antiangiogenic therapy will be more challenging than originally thought. It is now apparent that new methods and surrogate markers to assess these agents' biological activity are crucial for their successful development. This review summarises the currently available clinical data on the development of surrogate markers of angiogenesis inhibitors.

show abstract

Pretreatment Plasma Levels of Fibrinopeptide-A (FPA), D-Dimer (DD), and von Willebrand Factor (vWF) in Patients with Ovarian Carcinoma

Cited by 55 publications

References 0 publications

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma

Surrogate markers in antiangiogenesis clinical trials

Contact Info

Product

Resources

About